Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Transplantation and Cellular Therapy|March 29, 2021
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell TransplantationEmily C Liang, Lori S Muffly, Parveen Shiraz, et al.
The Annals of Thoracic Surgery|January 1, 2018
Imatinib Is Protective Against Ischemia-Reperfusion Injury in an Ex Vivo Rabbit Model of Lung InjuryJ Trent Magruder, Joshua C Grimm, Todd C Crawford, et al.
Blood Advances|March 25, 2018
Infusion of donor-derived CD8<sup>+</sup> memory T cells for relapse following allogeneic hematopoietic cell transplantationLori Muffly, Kevin Sheehan, Randall Armstrong, et al.
Annals of the American Thoracic Society|August 12, 2016
Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell TransplantGuang-Shing Cheng, Barry Storer, Jason W Chien, et al.
American Journal of Hematology|April 25, 2024
Management of post-autologous transplant relapse in patients with T-cell lymphomasOlivier Veilleux, Francisco Socola, Sally Arai, et al.
Blood Advances|September 17, 2020
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphomaWen-Kai Weng, Sally Arai, Andrew Rezvani, et al.
Clinical Proteomics|March 21, 2024
Quantitative proteomic analysis of HER2 protein expression in PDAC tumorsJamie Randall, Allison L Hunt, Aratara Nutcharoen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2017
Increased Foxp3<sup>+</sup>Helios<sup>+</sup> Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T CellsYi-Bin Chen, Yvonne A Efebera, Laura Johnston, et al.
Transplantation and Cellular Therapy|April 29, 2021
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide EraAndrew Johnsrud, Abdullah Ladha, Lori Muffly, et al.
Blood Advances|September 14, 2021
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapyAndrew Johnsrud, Juliana Craig, John Baird, et al.
Pageof 9